UCHL1 and COVID-19: We included analysis of plasma UCHL1 in our study because UCHL1 has been shown to indicate moderate TBI39 and has been found to be elevated in COVID-19 intensive care unit (ICU) patients,31 although UCHL1 has been less successful in distinguishing mild TBI.40,41 Despite this, UCHL1 was the only plasma biomarker that showed significant differences among visits within the SARS-CoV-2-positive participants, with plasma UCHL1 concentration at visit 3 being significantly greater than UCHL1 concentrations at visits 1 and 2.